Islay Capital Management’s Rani Therapeutics RANI Stock Holding History

Islay Capital Management’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-9,611	Closed	-$7.31K	–	179
2026 Q2	$7.31K	Hold	9,611	–	–	﹤0.01%	185
2026 Q1	$7.06K	Hold	9,611	–	–	﹤0.01%	169
2025 Q4	$13K	Hold	9,611	–	–	0.01%	163
2025 Q3	$4.8K	Hold	9,611	–	–	﹤0.01%	183
2025 Q2	$4.94K	Hold	9,611	–	–	﹤0.01%	166
2025 Q1	$12.1K	Hold	9,611	–	–	0.01%	146
2024 Q4	$13.2K	Hold	9,611	–	–	0.01%	155
2024 Q3	$20.8K	Hold	9,611	–	–	0.01%	147
2024 Q2	$36.5K	Hold	9,611	–	–	0.03%	135
2024 Q1	$29.9K	Hold	9,611	–	–	0.02%	143
2023 Q4	$31.9K	Hold	9,611	–	–	0.02%	151
2023 Q3	$20.9K	Hold	9,611	–	–	0.02%	157
2023 Q2	$39.6K	Hold	9,611	–	–	0.03%	133
2023 Q1	$49.6K	Hold	9,611	–	–	0.05%	131
2022 Q4	$56.7K	Hold	9,611	–	–	0.07%	123
2022 Q3	$92K	Hold	9,611	–	–	0.11%	108
2022 Q2	$99K	Buy	+9,611	New	+$110K	0.1%	134

Other funds holding RANI

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Well Done LLC Holland, Michigan $732M AUM 14.62% 1-Year Est. Return

Traphagen Investment Advisors Oradell, New Jersey $1.46B AUM 14.92% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

ACT Advisors Asheville, North Carolina $308M AUM 16.31% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Glass Jacobson Investment Advisors Owings Mills, Maryland $326M AUM 13.52% 1-Year Est. Return

Islay Capital Management's RANI Position: Q3 2026 in Review

Islay Capital Management sold out of Rani Therapeutics (RANI) in Q3 2026, closing a stake of 9,611 shares — an estimated $7.31K sold.

Islay Capital Management first reported a position in RANI in Q2 2022 and held it in 17 quarters. The position peaked at $99K in Q2 2022. 11 funds tracked by Wall St. Rank hold RANI as of Q3 2026.

Islay Capital Management reported no remaining Rani Therapeutics position as of Q3 2026 after selling out during the quarter.
Islay Capital Management sold 9,611 Rani Therapeutics shares in Q3 2026, an estimated $7.31K.
Islay Capital Management first reported a position in Rani Therapeutics in Q2 2022 and held it in 17 quarters.
Islay Capital Management's Rani Therapeutics position peaked at $99K in Q2 2022.
11 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2026.

Based on Islay Capital Management's 13F filing for Q3 2026, filed 20 Oct 2026.